Triple therapy for COPD: a crude analysis from a systematic review of the evidence.
José Luis López-CamposLaura Carrasco-HernandezEsther Quintana-GallegoCarmen Calero-AcuñaEduardo Márquez-MartínFrancisco Ortega-RuizJoan B SorianoPublished in: Therapeutic advances in respiratory disease (2020)
We systematically reviewed the current knowledge on fixed-dose triple therapies for the treatment of chronic obstructive pulmonary disease (COPD), with a specific focus on its efficacy versus single bronchodilation, double fixed dose combinations, and open triple therapies. Articles were retrieved from PubMed, Embase, and Scopus up to 3 August 2018. We selected articles with randomized controlled or crossover design conducted in patients with COPD and published as full-length articles or scientific letters, evaluating triple therapy combinations in a single or different inhaler, and with efficacy data versus monocomponents, double combinations, or open triple therapies. Our systematic search reported 108 articles, of which 24 trials were finally selected for the analysis. A total of 7 studies with fixed dose triple therapy combinations, and 17 studies with open triple therapies combinations. Triple therapy showed improvements in lung function [trough forced expiratory volume (FEV1) ranging from not significant (NS) to 147 ml], health status using the St. George's Respiratory Questionnaire [(SGRQ) from NS to 8.8 points], and exacerbations [risk ratio (RR) from NS to 0.59 for all exacerbations] versus single or double therapies with a variability in the response, depending the specific combination, and the comparison group. The proportion of adverse effects was similar between study groups, the exception being the increase in pneumonia for some inhaled corticosteroid (ICS) containing groups. The reviews of this paper are available via the supplementary material section.
Keyphrases
- lung function
- chronic obstructive pulmonary disease
- cystic fibrosis
- minimally invasive
- healthcare
- open label
- systematic review
- clinical trial
- randomized controlled trial
- double blind
- intensive care unit
- cross sectional
- placebo controlled
- case control
- phase iii
- bone marrow
- artificial intelligence
- mesenchymal stem cells
- phase ii